Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 1796 - 1796
Published: June 23, 2023
Triple negative breast cancer (TNBC) has a expression of estrogen receptors (ER), progesterone (PR), and human epidermal growth factor (HER2). The survival rate for TNBC is generally worse than other subtypes. treatment made significant advances, but certain limitations remain. Treatment can be challenging since the disease various molecular A variety options are available, such as chemotherapy, immunotherapy, radiotherapy, surgery. Chemotherapy most common these options. treated with systemic chemotherapy using drugs anthracyclines taxanes in neoadjuvant or adjuvant settings. Developing resistance to anticancer off-target toxicity primary hindrances chemotherapeutic solutions cancer. It imperative that researchers, clinicians, pharmaceutical companies work together develop effective TNBC. Several studies have suggested nanotechnology potential solution problem suboptimal treatment. In this review, we summarized possible TNBC, including targeted therapy, combination nanoparticle-based some future. Moreover, gave general information about terms its characteristics aggressiveness.
Language: Английский
Citations
134
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: March 11, 2024
Abstract Diet, serving as a vital source of nutrients, exerts profound influence on human health and disease progression. Recently, dietary interventions have emerged promising adjunctive treatment strategies not only for cancer but also neurodegenerative diseases, autoimmune cardiovascular metabolic disorders. These demonstrated substantial potential in modulating metabolism, trajectory, therapeutic responses. Metabolic reprogramming is hallmark malignant progression, deeper understanding this phenomenon tumors its effects immune regulation significant challenge that impedes eradication. Dietary intake, key environmental factor, can tumor metabolism. Emerging evidence indicates might affect the nutrient availability tumors, thereby increasing efficacy treatments. However, intricate interplay between pathogenesis other diseases complex. Despite encouraging results, mechanisms underlying diet-based remain largely unexplored, often resulting underutilization management. In review, we aim to illuminate various interventions, including calorie restriction, fasting-mimicking diet, ketogenic protein restriction high-salt high-fat high-fiber aforementioned diseases. We explore multifaceted impacts these encompassing their immunomodulatory effects, biological impacts, molecular mechanisms. This review offers valuable insights into application therapies
Language: Английский
Citations
66
Cancer and Metastasis Reviews, Journal Year: 2023, Volume and Issue: 42(3), P. 677 - 698
Published: July 11, 2023
Abstract Cancer is a multi-step process that can be viewed as cellular and immunological shift away from homeostasis in response to selected infectious agents, mutations, diet, environmental carcinogens. Homeostasis, which contributes importantly the definition of “health,” maintained, part by production short-chain fatty acids (SCFAs), are metabolites specific gut bacteria. Alteration composition bacteria, or dysbiosis, often major risk factor for some two dozen tumor types. Dysbiosis characterized diminished levels SCFAs stool, presence “leaky gut,” permitting penetration microbes microbial derived molecules (e.g., lipopolysaccharides) through wall, thereby triggering chronic inflammation. attenuate inflammation inhibiting activation nuclear kappa B, decreasing expression pro-inflammatory cytokines such necrosis alpha, stimulating anti-inflammatory interleukin-10 transforming growth beta, promoting differentiation naïve T cells into regulatory cells, down-regulate immune responses immunomodulation. SCFA function epigenetically histone acetyltransferases alter multiple genes activity many signaling pathways Wnt, Hedgehog, Hippo, Notch) contribute pathogenesis cancer. block cancer stem cell proliferation, potentially delaying development relapse targeting mutated tumors epidermal receptor, hepatocyte factor, MET) suppressors up-regulating PTEN p53). When administered properly, have advantages compared probiotic bacteria fecal transplants. In carcinogenesis, toxic against but not surrounding tissue due differences their metabolic fate. Multiple hallmarks also targets SCFAs. These data suggest may re-establish without overt toxicity either delay prevent various
Language: Английский
Citations
50
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 93, P. 105401 - 105401
Published: Jan. 25, 2024
Cancer is a major public health concern worldwide; it the second-highest cause of death in United States. According to projections cancer incidence and mortality rates throughout world for year 2023, triple-negative breast (TNBC) expected be leading related among women worldwide. Traditional strategies treatment TNBC have many drawbacks, such as drug resistance, toxicity etc. Discovering novel delivery techniques researching innovative, efficient methods important. This review discusses types subtypes TNBC. The problems associated with standard therapies, mechanism resistance highlights need develop therapeutic strategies. It provides information on relative prevalence severity cancer. Several approaches viz. targeted therapy, gene bacterial-mediated nanomedicine, immune checkpoint inhibitors, theranostic, radiotherapy, chemotherapy, immunotherapy, herbal AI-based TNBC, are discussed detail. Additionally, diagnostic techniques, including imaging biopsy, expression profiling, mammography, magnetic resonance imaging, ultrasound, computed tomography scan, positron emission immunohistochemistry, been effective treatment. in-depth analysis innovative individualized care serve patients better.
Language: Английский
Citations
19
Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)
Published: May 18, 2024
Abstract Immunotherapy has now garnered significant attention as an essential component in cancer therapy during this new era. However, due to immune tolerance, immunosuppressive environment, tumor heterogeneity, escape, and other factors, the efficacy of immunotherapy been limited with its application very small population size. Energy metabolism not only affects progression but also plays a crucial role escape. Tumor cells are more metabolically active need energy nutrients maintain their growth, which causes surrounding lack glucose, oxygen, nutrients, result decreased cell activity increased cells. On hand, utilize multiple metabolic pathways, for instance, cellular respiration, oxidative phosphorylation pathways normal function. Studies have shown that there is difference expenditure resting activated states. Notably, competitive uptake glucose main cause impaired T Conversely, glutamine competition often activation most transformation CD4 + into inflammatory subtypes. Excessive metabolite lactate impairs function NK Furthermore, PGE2 inhibits response by inhibiting Th1 differentiation, B function, activation. Additionally, tumor-suppressive M1 macrophages cancer-promoting M2 influenced metabolism. Therefore, vital factor involved reconstruction microenvironment. Noteworthy does program affect antigen presentation recognition cells, own functions, ultimately leading changes Metabolic intervention can improve tumors, increase immunogenicity thereby expanding who benefit from immunotherapy. Consequently, identifying crosstalk molecules link microenvironment would be promising anti-tumor strategy. AMPK (AMP-activated protein kinase) ubiquitous serine/threonine kinase eukaryotes, serving central regulator pathways. The sequential associated signaling cascades profoundly impacts dynamic alterations bioenergetics. By modulating responses, exerts influence on development, while playing pivotal regulating AMPK-mediated facilitates recruitment (TIME), impeding tumorigenesis, progression, metastasis. AMPK, between homeostasis, bioenergetics, immunity, will impact treatment management oncology patients. That being summarized, objective review pinpoint provide guidance development strategies.
Language: Английский
Citations
19
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Nov. 22, 2022
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of cancer. TNBC cells do not express well-known estrogen receptor, progesterone human epidermal growth factor receptor 2 (HER2) expressed by other subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine HER2-specific antibody therapies. To date, surgery, radiotherapy, systemic chemotherapy remain principal therapy options treatment. However, in numerous cases, these either result minimal clinical benefit or are nonfunctional, resulting disease recurrence poor prognosis. Nowadays, chimeric antigen T cell (CAR-T) becoming more established an option various types hematologic malignancies. CAR-Ts genetically engineered lymphocytes that employ body's immune system mechanisms to selectively recognize expressing tumor-associated antigens (TAAs) interest efficiently eliminate them. despite triumph CAR-T neoplasms, solid tumors, TNBC, has been much challenging. In this review, we will discuss success hematological neoplasms its caveats then summarize potential targetable TAAs studied different investigational stages.
Language: Английский
Citations
49
Cells, Journal Year: 2022, Volume and Issue: 11(22), P. 3692 - 3692
Published: Nov. 21, 2022
Chimeric antigen receptor (CAR)-expressing macrophages (CAR-M) have a great potential to improve cancer therapy, as shown from several recent preclinical studies. However, unlike CAR-T cell which has been widely studied, the efficacy and limitations of CAR-M cells remain be established. To address this issue, in present study, we compared three intracellular signaling domains (derived common γ subunit Fc receptors (FcRγ), multiple EGF-like-domains protein 10 (Megf10), CD19 cytoplasmic domain that recruits p85 phosphoinositide-3 kinase (PI3K), respectively) for their ability promote primary functions, investigated synergistic effect between kill tumor cells. We found CAR-MFcRγ exerted more potent phagocytic tumor-killing capacity than CAR-MMegf10 CAR-MPI3K. demonstrated cytotoxicity against vitro. Mechanistically, inflammatory factors secreted by increased expression costimulatory ligands (CD86 CD80) on augmented inducing macrophage M1 polarization. The upregulated may fitness activation turn, achieving significantly enhanced cytotoxicity. Taken together, our study first time could synergize with cells, provides proof-of-concept novel combinational immunotherapy.
Language: Английский
Citations
41
Translational Oncology, Journal Year: 2024, Volume and Issue: 41, P. 101893 - 101893
Published: Jan. 29, 2024
Triple-negative breast cancer (TNBC) is a subtype of with poor prognosis. The number cases increased by 2.26 million in 2020, making it the most commonly diagnosed type world. TNBCs lack hormone receptor (HR) and human epidermal growth factor 2 (HER2), which limits treatment options. Currently, paclitaxel-based drugs combined other chemotherapeutics remain main for TNBC. There currently no consensus on best therapeutic regimen However, there have been successful clinical trials exploring large-molecule monoclonal antibodies, small-molecule targeted drugs, novel antibody-drug conjugate (ADC). Although antibodies produced success, their large molecular weight can limit benefits. It worth noting that past 30 years, FDA has approved small molecule HER2-positive cancers. effective targets occurrence drug resistance pose significant challenges To improve prognosis TNBC, crucial to search overcome resistance. This review examines efficacy, adverse effects, mechanisms, potential solutions both monotherapies combination therapies. New targets, including nuclear export protein 1 (XPO1) hedgehog (Hh), are emerging as options researchers become integrated into Additionally, growing interest degradation chimeras (PROTACs), degraders rogue proteins, future therapy direction. provides potentially valuable insights implications.
Language: Английский
Citations
13
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: March 21, 2024
Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations inducing complete tumour regression spurred researchers to explore new approaches targeting tumours resistant current immunotherapies. OVs, both natural genetically engineered, selectively replicate within cells, lysis while sparing normal tissues. Recent advancements clinical research genetic engineering enabled the development of targeted viruses that modify microenvironment, triggering anti-tumour responses exhibiting synergistic effects with other therapies. Several OVs been studied breast including adenovirus, protoparvovirus, vaccinia virus, reovirus, herpes simplex type I (HSV-1). These modified or engineered enhance tumour-selective replication, reduce toxicity, improve oncolytic properties.Newer generations such Oncoviron Delta-24-RGD exhibit heightened replication selectivity enhanced anticancer effects, particularly models. Clinical trials explored efficacy safety various treating different cancers, melanoma, nasopharyngeal carcinoma, head neck cancer, gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) Oncorine have. approved advanced melanoma respectively. However, adverse reported some cases, flu-like symptoms rare instances severe complications fistula formation. Although no OV specifically ongoing preclinical focus on four groups viruses. mild low-grade fever nausea observed, effectiveness monotherapy remains insufficient. Combination strategies integrating chemotherapy, radiotherapy, immunotherapy, show promise improving therapeutic outcomes. holds substantial potential demonstrating trials. Multi-approach combining conventional therapies more than monotherapy, signalling hopeful future OV-based treatments.
Language: Английский
Citations
11
Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)
Published: July 11, 2024
Abstract As one of the significant challenges to human health, cancer has long been a focal point in medical treatment. With ongoing advancements field medicine, numerous methodologies for therapy have emerged, among which oncolytic virus gained considerable attention. However, viruses still exhibit limitations. Combining them with various therapies can further enhance efficacy treatment, offering renewed hope patients. In recent research, scientists recognized promising prospect amalgamating diverse treatments, potentially surmounting restrictions singular approaches. The central concept this combined revolves around leveraging incite localized tumor inflammation, augmenting immune response immunotherapeutic efficacy. Through approach, patient's system better recognize and eliminate cells, simultaneously reducing evasion mechanisms against system. This review delves deeply into latest research progress concerning integration treatments its role types therapy. We aim analyze mechanisms, advantages, potential challenges, future directions combination By extensively exploring field, we instill fight cancer.
Language: Английский
Citations
11